What's New at Charles River
   
 
 
   
   

Charles River Acquires Cerebricon LTD

August 4, 2009 – Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has acquired Cerebricon Ltd. Cerebricon, located in Kuopio, Finland, brings together MRI (magnetic resonance imaging) techniques, biomarkers and behavioral measurements in gold standard assays for acute neurology (such as stroke and spinal cord injury), chronic neurology (including multiple sclerosis and Alzheimer’s and Parkinson’s disease) and psychiatry (exemplified by ADHD, schizophrenia and depression).

Through our Discovery and Imaging Services group, which includes MIR Preclinical Services (acquired in 2008) and Piedmont Research Center (acquired in 2009), we have established ourselves as a premier provider of non-GLP pharmacology and in vivo imaging services for the evaluation of compound efficacy. Our therapeutic areas of expertise now span oncology, cardiovascular, metabolism, inflammation and CNS, all of which are areas of increasing R&D focus.

For more information, please call 1.877.CRIVER.1 (1.877.274.8371) or email us at askcharlesriver@crl.com.

   
Discover the full range of Charles River Products and Services
The Source

For more information, contact us at:

1.877.CRIVER.1 (1.877.274.8371)
askcharlesriver@crl.com

view all

News & Events

view all
Apr 11 - Access New and Updated Clinical Pa...
Mar 20 - TARGATT™ Mouse for Reliable Target...
Jun 10-Jun 13 - Barcelona, Spain - FELASA - SECAL 2013
May 21-May 24 - Berlin, Germany - RDD Europe 2013
May 23-May 23 - East Lansing, Michigan, USA - The Ins and Outs of Transgenic Colongy Ma...

Charles River Laboratories, Inc.